Clinical Trials for Autoinflammatory Diseases

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
http://www.clinicaltrials.gov/ct2/show/NCT00770601?term=NOMID&rank=1
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
http://www.clinicaltrials.gov/ct2/show/NCT00069329?term=NOMID&rank=2
Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)
http://www.clinicaltrials.gov/ct2/show/NCT00059748?term=NOMID&rank=3
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)
http://www.clinicaltrials.gov/ct2/show/NCT01213641?term=Cryopyrin&rank=5
Pathogenesis of Physical Induced Urticarial Syndromes (includes FCAS)
http://www.clinicaltrials.gov/ct2/show/NCT00887939?term=Cryopyrin&rank=7
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada (not yet recruiting)
http://www.clinicaltrials.gov/ct2/show/NCT01105507?term=Cryopyrin&rank=1
CAPS Clinical Trial with Ilaris in Japan
Japanese CAPS patients over the age of 2 years can enroll in this study with the new medication Ilaris.
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease (not yet recruiting)
http://www.clinicaltrials.gov/ct2/show/NCT01211977?term=MWS&rank=5